SmallCaps Podcast

Prescient Therapeutics (ASX: PTX) managing director and chief executive officer Steven Yatomi-Clarke joins Small Caps to discuss the company's novel approach to treating cancer using targeted and cellular therapy. Prescient Therapeutics is the only ASX-listed company developing CAR-T technology, which is a type of cellular therapy that reprograms a cancer patient’s immune cells to recognise and destroy cancer. The clinical stage oncology company recently announced it will be teaming up with the Peter MacCallum Cancer Centre to advance its CAR-T therapy.

See omnystudio.com/listener for privacy information.

Incannex Healthcare (ASX: IHL) chief medical officer Dr Sud Agarwal joins Small Caps to discuss the company's clinical trials involving medicinal cannabis to treat a number of ailments including: obstructive sleep apnoea (OSA), sepsis associated acute respiratory distress syndrome (SAARDS) and traumatic brain injury (TBI).

See omnystudio.com/listener for privacy information.

Credit Intelligence (ASX: CI1) executive chairman Jimmie Wong joins Small Caps to discuss the company's expansion into the Australian market with the acquisition of ChapterTwo. Also joining the discussion is ChapterTwo Australia director Chris Mushan. Mr Wong points out Credit Intelligence’s primary business in bankruptcy, debt restructuring and negotiation services means the company’s revenue and growth are strong during challenging economic conditions such as those brought on by COVID-19. In a June update, Credit Intelligence revealed it expected 2020 full year revenue to rise 125% to about $13.5 million.

See omnystudio.com/listener for privacy information.

BMG Resources (ASX: BMG) managing director Bruce McCracken speaks with Small Caps about the company’s move into the gold space and the acquisition of Abercromby, Invincible and South Boddington projects. Mr McCracken noted Abercromby had walk up drill targets and historic drill results include 57.5m at 5.73g/t gold. He added the mineralisation was shallow and supported an open pit-style operation. The company plans to drill and firm up a maiden resource at the project as soon as practicable.

See omnystudio.com/listener for privacy information.

Trigg Mining (ASX: TMG) managing director Keren Paterson joins Small Caps to discuss the latest news from the company's wholly-owned Lake Throssell sulphate of potash (SOP) project in Western Australia.

See omnystudio.com/listener for privacy information.

OliveX (NSX: OLX) chief executive officer Keith Rumjahn and executive director Xavier Kris join Small Caps to discuss the company's recent listing on the NSX. OliveX raised over $2 million to help roll-out its flagship KARA Smart Fitness and Mirror applications across Asia. Its services users in over 170 countries, enabling brands, influencers and fitness coaches to engage with consumers at home. The company is a subsidiary of former ASX-listed game developer Animoca Brands which retains a 33% stake in the business.

See omnystudio.com/listener for privacy information.

Shree Minerals (ASX: SHH) director Sanjay Loyalka joins Small Caps to discuss the company looking to re-start iron ore mining from its Nelson Bay River project following the recent improvement in prices and customer demand. The company has also increased its exposure to gold space after revealing in July it had applied for exploration licences in the Albany-Fraser Belt in WA. Additionally, Shree has applied for prime land in New South Wales’ Eastern Lachlan Fold Belt in proximity to known gold deposits.

See omnystudio.com/listener for privacy information.

PharmAust (ASX: PAA) executive chairman and CEO Dr Roger Aston joins Small Caps to discuss the company's latest news on monepantel which is set to commence a Phase 1 COVID-19 trial in humans in the near term. This comes after successfully repeating a second round of in-vitro anti-viral confirmatory testing, demonstrating anti-SARS-CoV-2 activity of both its monepantel and monepantel sulfone drug candidates. Dr Aston also discusses US veterinary pharmaceutical company Elanco US Inc decision not to proceed with exercising its option to develop monepantel as a cancer treatment for dogs and what this means for the company.

See omnystudio.com/listener for privacy information.

Tony Locantro, investment manager at Alto Capital, joins Small Caps to share his views on what's taking place in the stock market, where opportunity may lay and what might come next.

See omnystudio.com/listener for privacy information.

John Borshoff joins Small Caps to share his views on the uranium market and where he believes it's headed. John discusses his journey at Paladin Energy (ASX: PDN) in the 1990’s where he founded and ran the company taking it from a market cap of $2 million to $4.5 billion. One of the legendary stories in the mining space. We discuss John’s current company Deep Yellow (ASX: DYL) which is also operating in Namibia and on the hunt for uranium.

See omnystudio.com/listener for privacy information.